|
Notification of cessation of securities - IIQ
|
30 June 2023 at 2:40pm
|
|
SubB2M/CA15.3 Clinical Validation Data Investor Presentation
|
29 June 2023 at 11:10am
|
|
INOVIQ Investor Briefing
|
27 June 2023 at 2:30pm
|
|
Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test
|
27 June 2023 at 9:40am
|
|
ISEV Meeting Presentations
|
19 May 2023 at 9:40am
|
|
Appendix 4C and Quarterly Activities Report - March 2023
|
28 April 2023 at 9:50am
|
|
INOVIQ to present new EXO-NET data at ISEV Annual Meeting
|
19 April 2023 at 10:20am
|
|
Change of Director's Interest Notice - Philip Powell
|
7 March 2023 at 9:30am
|
|
Change of Director's Interest Notice - Philip Powell
|
6 March 2023 at 9:45am
|
|
Appendix 4D and Half Year Financial Report
|
24 February 2023 at 9:40am
|
|
Positive results for SubB2M Breast Cancer Test
|
8 February 2023 at 10:25am
|
|
Notification regarding unquoted securities - IIQ
|
1 February 2023 at 1:20pm
|
|
Notification of cessation of securities - IIQ
|
1 February 2023 at 9:20am
|
|
Appendix 4C & Quarterly Activities Report - December 2022
|
31 January 2023 at 9:30am
|
|
Final Director's Interest Notice
|
14 December 2022 at 11:05am
|
|
Resignation of Director
|
14 December 2022 at 8:45am
|
|
Positive EXO-NET Results in Ovarian Cancer
|
13 December 2022 at 10:05am
|
|
MST Access Diagnostics Forum Presentation
|
5 December 2022 at 10:30am
|
|
Change in substantial holding
|
30 November 2022 at 1:20pm
|
|
Results of 2022 Annual General Meeting
|
28 November 2022 at 3:50pm
|
|
CEO AGM Presentation
|
28 November 2022 at 10:25am
|
|
INOVIQ Settles Legal Proceedings
|
28 November 2022 at 10:20am
|
|
Commercial and R&D Update
|
25 November 2022 at 9:45am
|
|
Healthcare Conference Investor Presentation
|
10 November 2022 at 11:50am
|
|
Appendix 4C - Statement pursuant to Listing Rule 4.7C.3
|
4 November 2022 at 10:20am
|
|
IIQ Appendix 4C & Quarterly Activities Report-September 2022
|
28 October 2022 at 10:15am
|
|
Canadian Patent Granted for BARD1 Technology
|
27 October 2022 at 2:35pm
|
|
Investor Presentation
|
27 October 2022 at 11:30am
|
|
Notice of Annual General Meeting
|
27 October 2022 at 10:30am
|
|
Receipt of R&D Tax Incentive Refund
|
14 October 2022 at 10:10am
|
|
INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
|
13 October 2022 at 10:00am
|
|
Appendix 4G and Corporate Governance Statement
|
12 October 2022 at 8:40am
|
|
Appointment/Resignation of CFO and Company Secretary
|
6 October 2022 at 10:00am
|
|
Notification of cessation of securities - IIQ
|
3 October 2022 at 3:40pm
|
|
Notice required under listing rule 3.13.1
|
3 October 2022 at 9:00am
|
|
2022 Annual Report and update on results
|
28 September 2022 at 9:45am
|
|
Appendix 4E and Preliminary Financial Report
|
30 August 2022 at 7:05pm
|
|
IIQ Investor Presentation
|
9 August 2022 at 10:45am
|
|
INOVIQ Investor Briefing Invitation - June 2022 Quarter
|
4 August 2022 at 10:30am
|
|
IIQ Appendix 4C & Quarterly Activities Report - June 2022
|
27 July 2022 at 9:40am
|
|
Positive SubB2M IHC Results for Melanoma
|
26 July 2022 at 10:40am
|
|
hTERT US Patent Granted
|
22 July 2022 at 9:30am
|
|
INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out
|
21 July 2022 at 9:10am
|
|
SubB2M US Patent Grant and Program Update
|
1 July 2022 at 10:20am
|
|
INOVIQ&University of Sydney Present New EXO-NET Data at ISEV
|
27 May 2022 at 10:00am
|
|
Change of Director's Interest - Philip Powell
|
16 May 2022 at 8:50am
|
|
IIQ Investor Presentation
|
10 May 2022 at 9:05am
|
|
Change of Director's Interest - Dr Geoffrey Cumming
|
9 May 2022 at 8:55am
|
|
Change of Director's Interest - Philip Powell
|
4 May 2022 at 9:00am
|
|
INOVIQ Investor Briefing Invitation
|
3 May 2022 at 1:30pm
|
